Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.39 |
| ▸ | CASR | P41180 | 11/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19435492 | 0.86 | SLC22A12 (0.51) | SLC22A12 | |
| SCHEMBL28388169 | 0.81 | SLC22A12 (0.36) | SLC22A12 | |
| SCHEMBL19435555 | 0.81 | PDGFRB (0.39) | SLC22A12ERN1 | |
| SCHEMBL19435556 | 0.80 | SLC22A12 (0.55) | SLC22A12 | |
| SCHEMBL19435525 | 0.77 | ALDH1A1 (0.41) | SLC22A12 | |
| SCHEMBL19435477 | 0.77 | SLC22A12 (0.56) | SLC22A12 | |
| SCHEMBL19562877 | 0.76 | SLC22A12 (0.37) | SLC22A12 | |
| SCHEMBL19435467 | 0.75 | NPC1 (0.47) | — | |
| SCHEMBL19435505 | 0.75 | SLC22A12 (0.34) | SLC22A12 | |
| SCHEMBL19435533 | 0.71 | SLC22A12 (0.58) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241822-B1 | URAT1 INHIBITOR | NIPPON CHEMIPHAR CO (JP) | 2021-03-24 | — | — | EP | disclosed |
| CN-107108478-B | URAT1 inhibitors | 日本化学药品株式会社 | 2020-04-24 | — | — | CN | disclosed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3241822-A1 | URAT1 INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290795-A1 | URAT1 INHIBITOR | SLC10A1, XDH, URB2 | SLC22A12 512/4885CASR 1644/4885ERN1 1140/4885 |
| US-10173990-B2 | URAT1 inhibitor | SLC10A1, XDH, URB2 | SLC22A12 500/4885CASR 1699/4885ERN1 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.